[Business Wire] – CAMBRIDGE, Mass. & STOCKHOLM–(BUSINESSWIRE)– Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] experienced low bleeding rates, Biogen (NASDAQ:BIIB – . . . → Read More: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate® Published in Haemophilia Similar Articles: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair